CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended		119 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
OPERATING ACTIVITIES
Net loss	$ (2,413)	$ (2,197)	$ (156,973)
Non cash items:
Deferred tax expense	0	0	770
Depreciation and amortization, net of gain on sale	81	90	4,225
Non-cash stock compensation	49	28	5,014
Gain on sale of bone device business	0	0	(2,298)
In-process research and development	0	0	34,311
Change in other operating items:
Interest, income taxes and other current assets	(112)	186	1,363
Accounts payable	24	(159)	(859)
Accrued liabilities	306	(34)	(2,698)
Cash flows used in operating activities	(2,065)	(2,086)	(117,145)
INVESTING ACTIVITIES
Expenditures for furniture and equipment, net	0	0	(1,044)
Proceeds from sale of assets	0	4	7,176
Cash paid for assets of AzERx/CBI	0	0	(4,058)
Cash paid for patent rights	0	0	(1,028)
Purchases of investments	0	0	(282,538)
Maturities of investments	0	0	340,476
Cash flows provided by investing activities	0	4	58,984
FINANCING ACTIVITIES
Net proceeds from stock option exercises	0	0	4,612
Net proceeds from sale of stock	0	0	3,376
Common stock purchases	0	0	(1,041)
Cash flows provided by financing activities	0	0	6,947
NET DECREASE IN CASH AND CASH EQUIVALENTS	(2,065)	(2,082)	(51,214)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	6,258	10,205	55,407
CASH AND CASH EQUIVALENTS, END OF PERIOD	4,193	8,123	4,193
LipimetiX/AzERx/CBI [Member]
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:
Current assets acquired			29
Patent rights acquired			3,187
Liabilities acquired, and accrued acquisition costs			(457)
Original investment reversal			(750)
In-process research and development acquired			34,311
Noncontrolling interests			(667)
Common stock issued for acquisition			(31,217)
Cash paid			$ 4,436